Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Scheffler

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsSebastian Michels, Andreas Hans Scheel, Matthias Scheffler, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
Nature Methods|September 6, 2011
Toward the blood-borne miRNome of human diseasesAndreas Keller, Petra Leidinger, Andrea Bauer, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Scientific Data|August 13, 2021
OPTIMADE, an API for exchanging materials dataCasper W Andersen, Rickard Armiento, Evgeny Blokhin, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsSebastian Michels, Andreas Hans Scheel, Matthias Scheffler, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.
Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
Nature Methods|September 6, 2011
Toward the blood-borne miRNome of human diseasesAndreas Keller, Petra Leidinger, Andrea Bauer, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Scientific Data|August 13, 2021
OPTIMADE, an API for exchanging materials dataCasper W Andersen, Rickard Armiento, Evgeny Blokhin, et al.
Pageof 21